Cargando…

Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes

Diabetic nephropathy (DN) is one of the most perilous side effects of diabetes mellitus type 1 and type 2 (T1DM and T2DM).). It is known that sodium/glucose cotransporter 2 inhibitors (SGLT 2i) and glucagone like peptide-1 receptor agonists (GLP-1 RAs) have renoprotective effects, but the molecular...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ninčević, Vjera, Omanović Kolarić, Tea, Roguljić, Hrvoje, Kizivat, Tomislav, Smolić, Martina, Bilić Ćurčić, Ines
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6928920/ https://www.ncbi.nlm.nih.gov/pubmed/31757028 http://dx.doi.org/10.3390/ijms20235831

Ejemplares similares

Renoprotective Effect of Liraglutide Is Mediated via the Inhibition of TGF-Beta 1 in an LLC-PK1 Cell Model of Diabetic Nephropathy
por: Ninčević, Vjera, et al.
Publicado: (2022)

Pretreatment of Garlic Oil Extracts Hampers Epithelial Damage in Cell Culture Model of Peptic Ulcer Disease
por: Kuna, Lucija, et al.
Publicado: (2022)

Liraglutide Exerts Protective Effects by Downregulation of PPARγ, ACSL1 and SREBP-1c in Huh7 Cell Culture Models of Non-Alcoholic Steatosis and Drug-Induced Steatosis
por: Omanovic Kolaric, Tea, et al.
Publicado: (2022)

Molecular Mechanisms Linking Empagliflozin to Renal Protection in the LLC-PK1 Model of Diabetic Nephropathy
por: Mihaljević, Vjera, et al.
Publicado: (2022)

Mechanisms of Hepatic Cholestatic Drug Injury
por: Kolarić, Tea Omanović, et al.
Publicado: (2019)

Targeting the Wnt Signaling Pathway in Liver Fibrosis for Drug Options: An Update
por: Duspara, Kristina, et al.
Publicado: (2021)

Preclinical Models and Promising Pharmacotherapeutic Strategies in Liver Fibrosis: An Update
por: Kolaric, Tea Omanovic, et al.
Publicado: (2023)

Management of Glycemia during Acute Aerobic and Resistance Training in Patients with Diabetes Type 1: A Croatian Pilot Study
por: Ivandic, Marul, et al.
Publicado: (2023)

The Role of GLP1-RAs in Direct Modulation of Lipid Metabolism in Hepatic Tissue as Determined Using In Vitro Models of NAFLD
por: Petrovic, Ana, et al.
Publicado: (2023)

Drug-induced Fatty Liver Disease: Pathogenesis and Treatment
por: Kolaric, Tea Omanovic, et al.
Publicado: (2021)

Effect of COVID-19 on management of type 1 diabetes: Pushing the boundaries of telemedical healthcare
por: Bilic Curcic, Ines, et al.
Publicado: (2021)

Primary Care Provider Counseling Practices about Adverse Drug Reactions and Interactions in Croatia
por: Raguz Lucic, Nikola, et al.
Publicado: (2018)

Immunomodulatory Effects of SGLT2 Inhibitors—Targeting Inflammation and Oxidative Stress in Aging
por: Schönberger, Ema, et al.
Publicado: (2023)

Hypothyroidism and Nonalcoholic Fatty Liver Disease: Pathophysiological Associations and Therapeutic Implications
por: Kizivat, Tomislav, et al.
Publicado: (2020)

Therapeutic Perspectives of IL1 Family Members in Liver Diseases: An Update
por: Ćurčić, Ines Bilić, et al.
Publicado: (2022)

IMPACT OF GRAVES’ DISEASE AND ANTITHYROID DRUG THERAPY ON BONE MINERAL DENSITY – PATHOPHYSIOLOGICAL MECHANISMS AND CLINICAL RELEVANCE
por: Mudri, Dunja, et al.
Publicado: (2022)

Molecular Mechanisms Responsible for Diabetogenic Effects of COVID-19 Infection—Induction of Autoimmune Dysregulation and Metabolic Disturbances
por: Grubišić, Barbara, et al.
Publicado: (2023)

Biomarkers for Assessing Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus on Sodium–Glucose Cotransporter 2 Inhibitor Therapy
por: Khaznadar, Farah, et al.
Publicado: (2023)

Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals
por: Kishta, Sara, et al.
Publicado: (2020)

Wnt Inhibitors and Bone Mineral Density in Patients with Graves’ Disease Treated with Antithyroid Drugs: A Preliminary Prospective Study
por: Mudri, Dunja, et al.
Publicado: (2022)

Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update
por: Roguljic, Hrvoje, et al.
Publicado: (2021)

Antioxidant Pre-Treatment Reduces the Toxic Effects of Oxalate on Renal Epithelial Cells in a Cell Culture Model of Urolithiasis
por: Kizivat, Tomislav, et al.
Publicado: (2017)

Obesity Paradox in Chronic Liver Diseases: Product of Bias or a Real Thing?
por: Curcic, Ines Bilic, et al.
Publicado: (2019)

Representation of CYP3A4, CYP3A5 and UGT1A4 Polymorphisms within Croatian Breast Cancer Patients’ Population
por: Bojanic, Kristina, et al.
Publicado: (2020)

The role of direct oral anticoagulants in the era of COVID-19: are antiviral therapy and pharmacogenetics limiting factors?
por: Roguljić, Hrvoje, et al.
Publicado: (2022)

Hyperthyroidism and Wnt Signaling Pathway: Influence on Bone Remodeling
por: Mudri, Dunja, et al.
Publicado: (2023)

Association of Wnt Inhibitors, Bone Mineral Density and Lifestyle Parameters in Women with Breast Cancer Treated with Anastrozole Therapy
por: Bojanić, Kristina, et al.
Publicado: (2018)

LIFESTYLE RISK FACTORS AND BONE MASS IN RECURRENT STONE-FORMING PATIENTS: A CROSS-SECTIONAL STUDY IN 144 SUBJECTS
por: Marić, Ivana, et al.
Publicado: (2019)

SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
por: Rolek, Bartosz, et al.
Publicado: (2023)

Exploring new treatment options for polycystic ovary syndrome: Review of a novel antidiabetic agent SGLT2 inhibitor
por: Marinkovic-Radosevic, Jelena, et al.
Publicado: (2021)

GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off
por: Giugliano, Dario, et al.
Publicado: (2021)

Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System
por: Puglisi, Soraya, et al.
Publicado: (2021)

Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists
por: Khedagi, Apurva, et al.
Publicado: (2023)

Expected Health Benefits of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Older Adults
por: Dadwani, Rahul S., et al.
Publicado: (2023)

Role of galectin-3 in diagnosis and severity assessment of epicardial artery lesions in patients with suspected coronary artery disease
por: Bošnjak, Ivica, et al.
Publicado: (2023)

SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists
por: Abdelgadir, Elamin, et al.
Publicado: (2018)

Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
por: Arnold, Suzanne V., et al.
Publicado: (2022)

Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

SGLT2 Inhibitors and the Cardiorenal Continuum: A Paradigm Shift in the Treatment of Patients with T2D
por: Escalada, Javier
Publicado: (2022)

Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk
por: Goncalves, Edison, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tljjqfv7upvfh8rc0idiqt7d52